Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
A phase 1/2 trial of Balstilimab in colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Rottapharm Biotech, active and no longer recruiting.
Overview
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is a phase 1/2 interventional study registered as NCT05205330 by Rottapharm Biotech, with 107 participants enrolled, started 2021-11-23 and due to reach its primary completion in 2026-12. Interventions recorded: CR6086 and AGEN2034.
Similar pages
not linked directly; found by shared links- TrialA Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Shares Balstilimab, Agenus and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TreatmentBotensilimab
Shares Agenus, Colorectal cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialFeasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.